Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GXV813 · 1 trial · 1 indication
PANSS is a 30-item rating scale used to assess the positive, negative, and general psychopathy symptoms of schizophrenia. PANSS total score ranges from 30 to 120 , where a higher score indicates greater severity.
| Arm | Type | Description |
|---|---|---|
| GXV813 | EXPERIMENTAL | GXV813 administered orally. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered orally. |
| Name | Type | Description |
|---|---|---|
| GXV813 | DRUG | GXV813 administered orally. |
| Placebo | DRUG | Placebo administered orally. |
Inclusion Criteria: 1. Participant is aged 18 to 65 years, inclusive, at screening 2. Participant is capable of providing informed consent 3. Participant has a primary diagnosis of schizophrenia, established by a comprehensive psychiatric evaluation based on the DSM-5 (American Psychiatric Associat...
GXV813 is an investigational small molecule being developed for the treatment of schizophrenia. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied in hospitalized adults with schizophrenia to assess its safety, tolerability, and treatment response.
GXV813 is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting a Phase 2 clinical trial of GXV813 in patients with schizophrenia.
GXV813 is in Phase 2 clinical development for schizophrenia. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 2 trial is currently recruiting participants in the United States and Bulgaria.
GXV813 is being studied in one active Phase 2 clinical trial with the identifier NCT07467993. This randomized, double-blind, placebo-controlled study is assessing the safety, tolerability, and treatment response of GXV813 in hospitalized adults with schizophrenia. The trial aims to enroll 142 participants aged 18 years and older.
GXV813 is a small molecule therapeutic being developed for schizophrenia. The specific molecular target or mechanism of action has not been disclosed in available information. The drug is currently being evaluated in a Phase 2 clinical trial to determine its safety and efficacy in treating schizophrenia.